Differences between patients', physicians' and pharmacists' preferences for treatment products in haemophilia: a discrete choice experiment

• Published in: Haemophilia : the official journal of the World Federation of Hemophilia Vol. 11; no. 6; pp. 589 - 597
• Main Authors: Mantovani, L. G., Monzini, M. S., Mannucci, P. M., Scalone, L., Villa, M., Gringeri, A.
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Science Ltd 01-11-2005
• Subjects: Adolescent; Adult; Attitude of Health Personnel; Choice Behavior; coagulation factor concentrates; Cohort Studies; conjoint analysis; discrete choice experiment; Factor IX - adverse effects; Factor IX - antagonists & inhibitors; Factor IX - therapeutic use; Factor VIII - adverse effects; Factor VIII - antagonists & inhibitors; Factor VIII - therapeutic use; haemophilia; Hemophilia A - drug therapy; Hemophilia A - psychology; Hemophilia B - drug therapy; Hemophilia B - psychology; Humans; inhibitor; Male; Middle Aged; Patient Satisfaction; Pharmacists - psychology; Physicians - psychology; preferences; Severity of Illness Index
• ISSN: 1351-8216; 1365-2516
• DOI: 10.1111/j.1365-2516.2005.01159.x

The provision of health care to patients with haemophilia through replacement of the deficient coagulation factor is the result of a complex interaction between patients, physicians and policy makers, each carrying their individual sets of preferences. Preferences of patients, physicians and pharmacists towards perceived viral safety, risk of inhibitor development, infusion frequency during prophylaxis, pharmaceutical dosage form, distribution modes and price were evaluated by conjoint analysis, using a discrete choice experiment. Overall 178 patients’, 69 physicians and 58 pharmacists completed the study. Patients, physicians and pharmacists displayed preferences: (i) similar in direction and strength for risk of inhibitors and frequency of prophylaxis, (ii) similar in direction, but not in strength for perceived viral safety and price, with patients showing lower strength compared with physicians and pharmacists, and (iii) dissimilar in direction and/or strength for: (i) dosage form, which tested important only for pharmacists and (ii) distribution mode, which tested important for patients and physicians only. Our study provides evidence of the differences between different stakeholders in the preferences towards haemophilia replacement therapy, indicating that different opinions should be taken into account when planning optimal care.